David Matthew T. - 12 Jan 2024 Form 4 Insider Report for CorMedix Inc. (CRMD)

Reporting relationship: Chief Financial Officer
Issuer ticker: CRMD
Reported as of: 12 Jan 2024
Net transaction value: -$18,100
SEC form: 4
Accepted by SEC: 17 Jan 2024, 20:10:50 UTC
Prior SEC filing: 18 Jan 2023
Next SEC filing: 06 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew T David

Key filing fact

David Matthew T. filed Form 4 for CorMedix Inc. (CRMD) on 17 Jan 2024.

Key facts

This page summarizes David Matthew T.'s Form 4 filing for CorMedix Inc. (CRMD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jan 2024, 20:10.

Change

Previous filing in this sequence was filed on 18 Jan 2023.
Current net transaction value: -$18,100.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRMD transaction

Common Stock

Award

Transaction value: $0
Shares: +50,000
Change %: +1587%
Price: $0.000000
Shares after: 53,150
Date: 12 Jan 2024
Ownership: Direct
Footnotes: F1

CRMD transaction

Common Stock

Tax liability

Transaction value: $18,100
Shares: -5,216
Change %: -9.8%
Price: $3.47
Shares after: 47,934
Date: 12 Jan 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRMD transaction Derivative

Stock Option (Right to Buy Common Stock)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 12 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $3.47
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units ("RSUs") were granted on 01/12/2024. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These RSUs vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

Footnote F2

These options were granted on 01/12/2024. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.